Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

ClinicalTrials.gov ID: NCT02954536

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02954536. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.

Study identification

NCT ID: NCT02954536
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Enrollment: 37 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 3, 2016 (Actual)
Primary completion: Jun 1, 2022 (Actual)
Completion: Mar 14, 2023 (Actual)
Last update posted: Mar 16, 2023

2016 – 2023

United States locations

U.S. sites: 8
U.S. states: 2
U.S. cities: 8

Facility	City	State	ZIP	Site status
Memoral Sloan Kettering Cancer Center	Basking Ridge	New Jersey	—	—
Memorial Sloan Kettering Monmouth	Middletown	New Jersey	07748	—
Memorial Sloan Kettering Bergen	Montvale	New Jersey	07645	—
Memorial Sloan Kettering Commack	Commack	New York	11725	—
Memorial Sloan Kettering Westchester	Harrison	New York	10604	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Memorial Sloan Kettering Rockville Centre	Rockville Centre	New York	—	—
Memorial Sloan Kettering Nassau	Uniondale	New York	11553	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02954536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 16, 2023 · Synced Nov 12, 2026